New York State Teachers Retirement System Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

New York State Teachers Retirement System decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 360,161 shares of the medical device company’s stock after selling 6,147 shares during the quarter. New York State Teachers Retirement System’s holdings in DexCom were worth $28,010,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in DXCM. Crossmark Global Holdings Inc. increased its position in shares of DexCom by 1.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after acquiring an additional 182 shares during the period. GPS Wealth Strategies Group LLC grew its stake in DexCom by 13.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after purchasing an additional 185 shares during the last quarter. Peterson Wealth Services increased its holdings in shares of DexCom by 7.1% in the fourth quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock valued at $236,000 after purchasing an additional 201 shares during the period. Magnolia Capital Advisors LLC raised its stake in shares of DexCom by 2.6% in the fourth quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company’s stock worth $638,000 after purchasing an additional 210 shares during the last quarter. Finally, Riverview Trust Co lifted its holdings in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Morgan Stanley increased their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday. Oppenheimer reduced their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Raymond James lowered their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Citigroup increased their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $99.06.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,342 shares of company stock worth $3,628,069 over the last three months. Insiders own 0.30% of the company’s stock.

DexCom Trading Up 5.9 %

DXCM opened at $89.07 on Friday. The stock has a market capitalization of $34.79 billion, a PE ratio of 53.34, a P/E/G ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The business’s 50 day moving average price is $82.44 and its 200 day moving average price is $75.44.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. As a group, equities research analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.